miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1

Multiple Myeloma

(2017) Kenneth C. Anderson et al.   Journal of the National Comprehensive Cancer Network

Synthetic miR-34a Mimics as a Novel Therapeutic Agent for Multiple Myeloma: In Vitro and In Vivo Evidence

(2012) M. T. Di Martino et al.   CLINICAL CANCER RESEARCH

MicroRNAs in the Pathobiology of Multiple Myeloma

(2012) Marta Lionetti et al.   CURRENT CANCER DRUG TARGETS

Molecular Targets for the Treatment of Multiple Myeloma

(2012) Marco Rossi et al.   CURRENT CANCER DRUG TARGETS

Promises and Challenges of MicroRNA-based Treatment of Multiple Myeloma

(2012) P. Tagliaferri et al.   CURRENT CANCER DRUG TARGETS

Pathogenesis of Myeloma

(2011) Kenneth C. Anderson et al.   Annual Review of Pathology-Mechanisms of Disease

Overexpression of microRNA-29b induces apoptosis of multiple myeloma cells through down regulating Mcl-1

(2011) Yi-Kun Zhang et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Molecular Pathways: Targeting Proteasomal Protein Degradation in Cancer

(2011) S. M. Molineaux   CLINICAL CANCER RESEARCH

Significant Biological Role of Sp1 Transactivation in Multiple Myeloma

(2011) M. Fulciniti et al.   CLINICAL CANCER RESEARCH

Oncogenic Role of the E3 Ubiquitin Ligase NEDD4-1, a PTEN Negative Regulator, in Non-Small-Cell Lung Carcinomas

(2010) Nicola Amodio et al.   AMERICAN JOURNAL OF PATHOLOGY

Histone deacetylases are critical targets of bortezomib-induced cytotoxicity in multiple myeloma

(2010) J. Kikuchi et al.   BLOOD

Loss of BRCA1 function increases the antitumor activity of cisplatin against human breast cancer xenografts in vivo

(2010) Pierfrancesco Tassone et al.   CANCER BIOLOGY & THERAPY

Sp1/NFκB/HDAC/miR-29b Regulatory Network in KIT-Driven Myeloid Leukemia

(2010) Shujun Liu et al.   CANCER CELL

Development of a Lung Cancer Therapeutic Based on the Tumor Suppressor MicroRNA-34

(2010) J. F. Wiggins et al.   CANCER RESEARCH

Transcriptional suppression of mir-29b-1/mir-29a promoter by c-Myc, hedgehog, and NF-kappaB

(2010) Justin L. Mott et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

MiRNAs and Cancer

(2009) Rosa Visone et al.   AMERICAN JOURNAL OF PATHOLOGY

Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma

(2009) M. Fulciniti et al.   BLOOD

Bortezomib induces canonical nuclear factor- B activation in multiple myeloma cells

(2009) T. Hideshima et al.   BLOOD

MicroRNA 29b functions in acute myeloid leukemia

(2009) R. Garzon et al.   BLOOD

A High-Affinity Fully Human Anti-IL-6 mAb, 1339, for the Treatment of Multiple Myeloma

(2009) M. Fulciniti et al.   CLINICAL CANCER RESEARCH

Effect of the Cytochrome P450 2C19 Inhibitor Omeprazole on the Pharmacokinetics and Safety Profile of Bortezomib in Patients with Advanced Solid Tumours, Non-Hodgkinʼs Lymphoma or Multiple Myeloma

(2009) David I. Quinn et al.   CLINICAL PHARMACOKINETICS

Integrative high-resolution microarray analysis of human myeloma cell lines reveals deregulated miRNA expression associated with allelic imbalances and gene expression profiles

(2009) Marta Lionetti et al.   GENES CHROMOSOMES & CANCER

MicroRNAs in the ontogeny of leukemias and lymphomas

(2009) Muller Fabbri et al.   LEUKEMIA & LYMPHOMA

Causes and consequences of microRNA dysregulation in cancer

(2009) Carlo M. Croce   NATURE REVIEWS GENETICS

NF-κB–YY1–miR-29 Regulatory Circuitry in Skeletal Myogenesis and Rhabdomyosarcoma

(2008) Huating Wang et al.   CANCER CELL

Telomerase inhibitor GRN163L inhibits myeloma cell growth in vitro and in vivo

(2008) M A Shammas et al.   LEUKEMIA

miR-29 miRNAs activate p53 by targeting p85α and CDC42

(2008) Seong-Yeon Park et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

MicroRNA 29c is down-regulated in nasopharyngeal carcinomas, up-regulating mRNAs encoding extracellular matrix proteins

(2008) S. Sengupta et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA